Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NQO1-AS gapmer
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intrathecal, Intravitreal, Intranasal, Parenteral
01
Overview
NQO1-AS gapmer is an antisense oligonucleotide (specifically a chimeric gapmer) designed to target and knock down NQO1-AS (NQO1 antisense RNA), a long non-coding RNA (lncRNA) transcribed from the antisense strand of the 3' UTR of the NQO1 gene. In metastatic breast cancer, NQO1-AS is upregulated and forms a stable duplex with NQO1 mRNA, stabilizing it and increasing the expression of the cytoprotective redox enzyme NADPH quinone dehydrogenase 1 (NQO1). This metabolic reprogramming protects cancer cells from oxidative stress and ferroptosis, facilitating metastatic colonization (particularly in the lungs). By utilizing NQO1-AS gapmers to knock down NQO1-AS, researchers can destabilize NQO1 mRNA, reduce NQO1 protein levels, and sensitize metastatic breast cancer cells to oxidative damage and ferroptosis, thereby inhibiting metastatic progression.
- Other names
- NQO1-AS antisense oligonucleotideNQO-1-AS antisense oligonucleotideNQO 1-AS antisense oligonucleotideNQO1-AS gapmer ASONQO-1-AS gapmer ASONQO 1-AS gapmer ASO
02
Targets
NQO1
Beyond the preview
Go deeper on NQO1-AS gapmer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NQO1-AS gapmer.